BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM

The BioPlex 2200 ANA Screen utilizes multi-analyte technology for the detection and quantification of eleven distinct autoantibodies in human serum or plasma, serving as an aid in the diagnosis of systemic autoimmune diseases. Its accompanying Medical Decision Support Software (MDSS) employs a k-Nearest Neighbor statistical algorithm to analyze these antibody profiles against a comprehensive database, suggesting potential disease associations to assist clinicians.

The BioPlex 2200 ANA Screen is a system intended for the qualitative screening of specific antinuclear antibodies (ANA), quantitative detection of antibody to dsDNA, and semi-quantitative detection of ten other autoantibodies (Chromatin, Ribosomal Protein, SS-A, SS-B, Sm, SmRNP, RNP, Scl-70, Jo-1, and Centromere B) from human serum or plasma. This system serves as an aid in diagnosing systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Scleroderma, Mixed Connective Tissue Disease (MCTD), and Polymyositis. The BioPlex 2200 Medical Decision Support Software (MDSS) is an optional tool used with the ANA Screen. It employs a k-Nearest Neighbor (kNN) pattern recognition algorithm, comparing a patient's eleven individual antibody results against a pre-established database of over 1,400 characterized sera to identify associated diagnostic patterns and suggest potential disease associations. The MDSS provides outputs such as "Negative" (all antibody levels below cutoffs), "No Association" (antibody levels show no association with MDSS profiles for systemic autoimmune diseases), or "Association with Disease," where it may propose up to two disease classifications based on the similarity of the current analysis to stored results. Clinical performance studies involved 908 prospective samples from rheumatology clinic patients and 222 normal blood donors. The ANA Screen itself showed overall sensitivity of 67.6% and specificity of 77.7% for targeted diseases. The MDSS's performance, including its agreement with physician diagnoses for various autoimmune conditions (e.g., 85.3% agreement for SLE in patients with positive antibodies, 86.7% for Sjogren's Syndrome), likelihood ratios, and odds ratios, was evaluated to demonstrate its utility in aiding differential diagnosis and determining appropriate additional serological testing.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. Considering the k-Nearest Neighbor algorithm's reliance on a pre-established database, how sensitive is the Medical Decision Support Software (MDSS) performance to variations in patient demographics or disease prevalence not represented in the initial 1,400+ characterized sera?; The document notes that patients with Rheumatoid Arthritis (RA) may result in a Systemic Lupus Erythematosus (SLE) association from MDSS; what specific antibody patterns common in RA lead to this potential misclassification, and are there plans to refine the algorithm to better distinguish these conditions?; For the MDSS outputs 9 through 15 (e.g., Polymyositis/SLE) that were not observed in the clinical trial, what was the theoretical or preclinical basis for their inclusion as potential outputs, and how will their clinical validity be established or monitored post-market?; How does the MDSS algorithm weigh the significance of different antibody levels when multiple autoantibodies are detected at varying concentrations, particularly when determining the one or two most probable disease associations?; Given the complexity of autoimmune diseases and the reported 49% agreement between referring and final diagnoses, what is the recommended clinical workflow for integrating MDSS results, especially when they conflict with initial clinical impressions or other laboratory findings?